SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that Jeffrey Stein, Ph.D., president and chief executive
officer, will be participating in a panel discussion at the 2017
Infectious Diseases Summit being held July 13-14 in Baltimore, Maryland.
The interactive panel will be part of the Summit’s 14th Anti-Infectives
Partnering & Deal-Making Conference that will focus on the types and
availability of economic incentives to spur innovation and development
of therapies to address rapidly emerging global health threats. Details
of the panel discussion are as follows:
Session Name: Pushing
and Pulling- What Incentives Help Spark Innovation in Antibiotic Drug
Discovery and Development?
Date and time: Friday, July
14, 2017 at 8:30 a.m. Eastern Time (ET)
Location: Royal
Sonesta, Baltimore
Dr. Stein is also the chairman of the Antimicrobials Working Group
(AWG), an industry-led coalition of emerging antimicrobial companies
that aims to provide a collective voice in policy and regulatory
solutions. He is widely recognized within the industry for his expertise
in the discovery and development of antimicrobials.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101 IV, through Phase 2
and developing CD201, its bispecific antibiotic immunotherapy, for the
treatment of multi-drug resistant Gram-negative bacterial infections.
CD101 IV has improved pharmacokinetics compared to existing
echinocandins and has the potential for expanded utility across patient
settings. CD101 IV is the only once-weekly product candidate in
development for the treatment and prevention of life-threatening
invasive fungal infections. CD201 is the first drug candidate selected
from Cidara’s novel Cloudbreak™ platform, the first immunotherapy
discovery platform designed specifically to create compounds that direct
a patient’s immune cells to attack and eliminate bacterial, fungal or
viral pathogens. Cidara has received a grant for up to $6.9 million from
CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance
the development of CD201. Cidara is headquartered in San Diego,
California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, and other attributes
of CD101 and CD201 and other potential product candidates, including the
potential for these compounds to successfully treat or prevent
infections, including those caused by resistant pathogens, and
potentially transform the way infectious diseases are treated, and the
potential for the Cloudbreak platform to result in future drug
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of Cidara’s
preclinical studies and clinical trials; regulatory developments in the
United States and foreign countries; changes in Cidara’s plans to
develop and commercialize its product candidates; Cidara’s ability to
obtain additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170706005160/en/
Cidara Therapeutics, Inc.
INVESTOR CONTACT:
Westwicke
Partners, LLC
Robert H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
